Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | F10 | P00742 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737053 | 0.88 | MEN1 (0.60) | LMNAMEN1MAPTKMT2AF10 | |
| SCHEMBL9938318 | 0.88 | MEN1 (0.70) | LMNAMEN1MAPTKMT2AF10 | |
| SCHEMBL930833 | 0.87 | MEN1 (0.62) | LMNAMEN1MAPTKMT2AF10 | |
| SCHEMBL5465044 | 0.86 | MAPT (0.61) | MEN1MAPTKMT2AF10F2 | |
| SCHEMBL9170741 | 0.86 | MEN1 (0.58) | MEN1MAPTKMT2AF10F2 | |
| SCHEMBL4256742 | 0.86 | CYP3A4 (0.59) | LMNACYP1A2CYP3A4MAOAMEN1 | |
| SCHEMBL16628147 | 0.85 | LMNA (0.83) | LMNACYP1A2CYP3A4MAOAMAPT | |
| SCHEMBL21612795 | 0.84 | F10 (0.55) | LMNACYP1A2CYP3A4MAOAMEN1 | |
| SCHEMBL5873911 | 0.84 | SMN1; SMN2 (0.58) | MAOAMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL9937715 | 0.84 | TDP1 (0.63) | MEN1MAPTKMT2AF10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| US-20070021407-A1 | Substituted quinolines as antitumor agents | ASTRAZENECA | 2007-01-25 | — | — | US | disclosed |
| WO-2004046118-A2 | 2-4-(DI-PHENYL-AMINO)-PYRIMIDINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021407-A1 | Substituted quinolines as antitumor agents | NR1H3, NR1H2, NR0B1 | LMNA 3425/4885CYP1A2 1345/4885CYP3A4 576/4885 |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | LMNA 994/4885CYP1A2 2251/4885CYP3A4 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.